Oseltamivir

證據等級: L5

預測適應症: 10 個

Oseltamivir: From Influenza to Pneumonia (Influenza-Associated)

Candidate selection note: TxGNN’s highest-scoring prediction for Oseltamivir was pyelonephritis (97.85%), but the evidence pack’s own review flags this as co-occurrence noise with no plausible mechanism (an antiviral drug has no antibacterial activity against a bacterial kidney infection). Ranks 2–7 and 10 are similarly flagged as noise with L5/Hold status. Of the ten predictions, only pneumonia (rank 8) and streptococcal pneumonia (rank 9) carry actual supporting evidence (L4, decision stage S1, “Research Question”). This report focuses on pneumonia, the most evidence-supported candidate.

One-Sentence Summary

Oseltamivir is a neuraminidase inhibitor established for treatment and prophylaxis of influenza A and B. The TxGNN model predicts a possible role in preventing/reducing severe pneumonia (viral and secondary bacterial) associated with influenza, supported by 50 clinical trials and 20 publications, though the mechanism is indirect and not yet clinically confirmed as a standalone pneumonia treatment.

Quick Overview

Item	Content
Original Indication	Not available in Evidence Pack (no SAHPRA licenses on file); based on known pharmacology, Oseltamivir is indicated for treatment/prophylaxis of Influenza A and B
Predicted New Indication	Pneumonia (influenza-associated, viral and secondary bacterial)
TxGNN Prediction Score	92.14%
Evidence Level	L4
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data is not available in this Evidence Pack (Data Gap DG002). Based on established pharmacological knowledge, Oseltamivir is a neuraminidase inhibitor that blocks release of newly formed influenza virus particles from infected respiratory epithelial cells, limiting viral spread within the airway.

Influenza infection is a well-documented risk factor for progression to pneumonia — both primary viral pneumonia and secondary bacterial pneumonia (notably Streptococcus pneumoniae and Staphylococcus aureus, including PVL-producing strains causing necrotizing pneumonia). Since Oseltamivir reduces viral replication, it may plausibly lower the incidence or severity of this downstream complication by shortening the window of viral-mediated epithelial damage that predisposes to bacterial superinfection.

This is an indirect, adjunctive mechanism, not a direct antimicrobial or anti-inflammatory effect on pneumonia itself. Preclinical work (e.g., McCullers 2004, PMID 15243927) shows oseltamivir improves survival in mouse models of post-influenza pneumococcal pneumonia, and observational/cohort data in humans associate early oseltamivir treatment with reduced pneumonia risk — but no trial has been designed with pneumonia (rather than influenza) as the primary endpoint. This is why the evidence pack scores this candidate L4 / decision stage S1 (“Research Question”) rather than a stronger tier.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01248715	Phase 4	Completed	1107	Effectiveness of empiric antiviral treatment for hospitalized community-acquired pneumonia during influenza season
NCT00707941	Phase 3	Completed	1190	Oseltamivir efficacy in reducing illness duration, viral shedding, and household transmission (Dhaka, Bangladesh cohort)
NCT00545532	Phase 3	Completed	228	Conventional vs double-dose oseltamivir in immunocompromised influenza patients — a group at elevated pneumonia risk
NCT01620307	Phase 2	Completed	38	Adjuvant mTOR inhibitor (rapamune) for severe H1N1 pneumonia with respiratory failure (oseltamivir as background therapy)
NCT03900988	Phase 3	Unknown	160	IV N-acetylcysteine + oseltamivir vs dextrose + oseltamivir in influenza complicated by lower respiratory tract infection
NCT00936013	Phase 4	Unknown	400	Chinese medicinal herbs + oseltamivir vs oseltamivir alone for H1N1 influenza pneumonia
NCT02561169	Phase 4	Terminated (n=1)	1	RCT of oseltamivir vs placebo in high-risk ED patients with influenza; primary outcome hospitalization
NCT02282384	Phase 4	Withdrawn	0	Pilot RCT of oseltamivir in outpatients with chronic pulmonary disease (feasibility study)
NCT00958776	Phase 3	Terminated	405	IV peramivir + standard of care vs standard of care alone (incl. oseltamivir) in hospitalized serious influenza
NCT05648448	Phase 2	Recruiting	3000	AD ASTRA adaptive platform trial comparing antiviral pharmacodynamics, including oseltamivir, in early influenza

Literature Evidence

PMID	Year	Type	Journal	Key Findings
24718923	2014	Cochrane Systematic Review	Cochrane Database Syst Rev	Systematic review of neuraminidase inhibitors for preventing/treating influenza in adults and children
40050867	2025	Review	Virology Journal	Antiviral treatment options for viral pneumonia, including oseltamivir’s mechanism
35993199	2022	Review	Journal of Global Health	Role of adjunctive oseltamivir, steroids, macrolides, vitamins for severe pneumonia in children (LMIC)
31189475	2019	Review	Critical Care	Prevention, diagnosis and treatment of influenza-related critical illness
39172994	2025	Cohort (FluSurv-NET)	Clinical Infectious Diseases	Timing of influenza antiviral therapy and risk of death in adults with influenza-associated pneumonia
15243927	2004	Preclinical (mouse model)	Journal of Infectious Diseases	Oseltamivir improved survival (0%→75%) in mouse model of secondary pneumococcal pneumonia after influenza
21760915	2011	Retrospective Cohort	PLoS ONE	Early oseltamivir administration reduced occurrence/severity of pandemic H1N1-associated pneumonia (Mexico)
15969875	2005	Review	Current Medical Research and Opinion	Risk of pneumonia and other complications of influenza-like illness in oseltamivir-treated patients
32527739	2020	Retrospective Cohort	European Respiratory Journal	Oseltamivir and influenza-related complications in children in primary care
39189087	2024	Retrospective Cohort	Influenza and Other Respiratory Viruses	Comparison of baloxavir vs oseltamivir effectiveness in preventing hospitalization/pneumonia in influenza B

South Africa Market Information

Oseltamivir currently has no SAHPRA registrations on file in this Evidence Pack (market_status: 未上市 / Not marketed, total_licenses: 0). No product name, dosage form, or approved indication text is available for South Africa at this time.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

(Note: Key warnings, contraindications, and DDI data are flagged as Blocking data gaps (DG001) in this Evidence Pack and could not be assessed here.)

Conclusion and Next Steps

Decision: Hold

Rationale:

The pneumonia signal has real but indirect mechanistic support (L4, decision stage S1, “Research Question”) — no trial has tested oseltamivir with pneumonia as a primary endpoint, and the drug has no direct antimicrobial activity against the bacterial pathogens implicated in secondary pneumonia.
Oseltamivir has zero SAHPRA registrations and is not currently marketed in South Africa, and safety data (warnings, contraindications, DDI) is a Blocking data gap — these must be resolved before any S1 safety screening can proceed.

To proceed, the following is needed:

SAHPRA-approved Professional Information (PI) — warnings, contraindications, drug interactions (DG001, Blocking)
Confirmed mechanism of action data via DrugBank/other pharmacological source (DG002, High)
Clarification of SAHPRA registration pathway/status for Oseltamivir in South Africa
A dedicated trial or well-controlled observational study evaluating oseltamivir’s effect specifically on pneumonia incidence/severity as a primary (not secondary) endpoint
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.